KalVista Pharmaceuticals (NASDAQ:KALV) Posts Earnings Results, Misses Expectations By $0.54 EPS

KalVista Pharmaceuticals (NASDAQ:KALV) released its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.54), reports. The firm had revenue of $13.69 million for the quarter, compared to analyst estimates of $39.14 million.

KalVista Pharmaceuticals Trading Down 0.1%

Shares of KalVista Pharmaceuticals stock traded down $0.04 during trading hours on Thursday, reaching $26.76. The company’s stock had a trading volume of 3,472,199 shares, compared to its average volume of 6,355,700. The company’s 50 day simple moving average is $20.20 and its 200 day simple moving average is $16.65. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals has a one year low of $9.83 and a one year high of $26.85.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on KALV shares. Needham & Company LLC downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 30th. Wall Street Zen downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 21st. Leerink Partners downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Citizens Jmp downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Finally, Stifel Nicolaus raised their price target on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Three investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $30.60.

Insiders Place Their Bets

In related news, insider Paul K. Audhya sold 2,686 shares of the stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $54,310.92. Following the sale, the insider owned 142,547 shares of the company’s stock, valued at $2,882,300.34. This trade represents a 1.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Brian Piekos sold 1,862 shares of the stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $20.22, for a total transaction of $37,649.64. Following the completion of the sale, the chief financial officer directly owned 18,150 shares in the company, valued at approximately $366,993. This trade represents a 9.30% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 263,937 shares of company stock worth $4,572,251. 4.30% of the stock is owned by company insiders.

Institutional Trading of KalVista Pharmaceuticals

Large investors have recently modified their holdings of the company. BNP Paribas Financial Markets increased its holdings in shares of KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter worth about $55,000. Truvestments Capital LLC increased its holdings in shares of KalVista Pharmaceuticals by 253.8% in the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after acquiring an additional 3,360 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of KalVista Pharmaceuticals by 816.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company’s stock worth $91,000 after acquiring an additional 7,180 shares during the period. Finally, Sei Investments Co. acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter worth about $145,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.